Canada-based Cardiome Pharma has received expanded indications from the Chinese Center for Drug Evaluation (CDE) for the use of its Aggrastat (tirofiban hydrochloride) in ST-segment elevation myocardial infarction (STEMI) patients intended for primary percutaneous coronary intervention (PCI).
The agency also approved Aggrastat high-dose bolus (HDB) regimen followed by a continuous infusion of 0.15mcg/kg/min for the treatment of patients with STEMI or acute coronary syndromes without ST elevation (NSTE-ACS).
Aggrastat is an intravenous (IV) non-peptidal antagonist of the glycoprotein (GP) IIb/IIIa platelet surface receptor associated with platelet aggregation.
It inhibits the binding of fibrinogen to the GP IIb/IIIa receptor to prevent the cross-linking or aggregation of platelets.
Leave a Reply